|
|
| Catalog Number |
413401 |
| Medical Device Problem Code |
Incorrect, Inadequate or Imprecise Result or Readings (1535)
|
| Health Effect - Clinical Code |
No Patient Involvement (2645)
|
|
Type of Reportable Event
|
Malfunction
|
|
Event or Problem Description
|
|
A customer in the united states notified biomérieux of discrepant results associated with vitek® 2 ast-gn70 test kit (reference 413401).The customer reported receiving an incorrect result on the api survey.On an escherichia coli isolate, ampicillin/sulbactam and cefepime were reported as sensitive.The expected results for these drugs were intermediate or resistant.There was no patient involved in this event.An internal biomérieux investigation will be initiated.
|
| |
|
Additional Manufacturer Narrative
|
|
An internal biomérieux investigation was initiated due to false results associated with the vitek® 2 ast-gn70 card when testing api survey strain ur-06 escherichia coli.Ampicillin/sulbactam (ams) and cefepime (fep) were reported as susceptible.The expected result for these drugs was resistant.The strain was submitted for investigation.The submitted strain was subcultured, and the identification was confirmed as e.Coli.Testing was performed on vitek 2 ast-gn70 cards from the customer lots (5900727403, 5900755403) and a random lot (5900650403), as well as agar dilution (ad) as the reference method for fep02n and sam01n formulations found on this card.Clsi breakpoints: ams = 8 (s) 16 (i) >/= 32 (r).Fep = 2 (s) 4-8 (sdd) >/=16 (r).Ampicillin/sulbactam mics = 8 (s), 4 (s), >/=32 (r) on the three(3) vitek 2 gn70 cards tested.Ams ad mic =32 (r).Cards and reference method are in agreement for one (1) card, and essential agreement error for the other two (2) cards, demonstrating a very major error for the vitek 2.Cefepime mics =1* on two cards mic = 2* on the remaining card, all with aes software modification to resistant due to a proposed esbl phenotype.Fep ad mic = 8, demonstrating as essential agreement error between vitek 2 and reference method.Conclusion: atypical survey strain.A complaint and quality review was performed, which did not identify this discrepancy as a systemic quality issue.
|
| |
|
Additional Manufacturer Narrative
|
|
As requested by fda on 17jul2023, 1950204-2018-00394 supplement 1 is being submitted as a correction for the previously submitted 1950204-2018-00394 supplement 2.1950204-2018-00394 supplement 2 was originally submitted on 07dec2018 and was erroneously coded as "follow-up # 2" instead of "follow-up #1".An internal biomérieux investigation was initiated due to false results associated with the vitek® 2 ast-gn70 card when testing api survey strain ur-06 escherichia coli.Ampicillin/sulbactam (ams) and cefepime (fep) were reported as susceptible.The expected result for these drugs was resistant.The strain was submitted for investigation.The submitted strain was subcultured, and the identification was confirmed as e.Coli.Testing was performed on vitek 2 astgn70 cards from the customer lots (5900727403, 5900755403) and a random lot (5900650403), as well as agar dilution (ad) as the reference method for fep02n and sam01n formulations found on this card.Clsi breakpoints: ams = 8 (s) 16 (i) >/= 32 (r).Fep = 2 (s) 4-8 (sdd) >/=16 (r).Ampicillin/sulbactam mics = 8 (s), 4 (s), >/=32 (r) on the three(3) vitek 2 gn70 cards tested.Ams ad mic =32 (r).Cards and reference method are in agreement for one (1) card, and essential agreement error for the other two (2) cards, demonstrating a very major error for the vitek 2.Cefepime mics =1* on two cards mic = 2* on the remaining card, all with aes software modification to resistant due to a proposed esbl phenotype.Fep ad mic = 8, demonstrating as essential agreement error between vitek 2 and reference method.Conclusion: atypical survey strain.A complaint and quality review was performed, which did not identify this discrepancy as a systemic quality issue.
|
| |
|
Search Alerts/Recalls
|
|
|